Lonza Pharma & Biotech and Innosieve Diagnostics announced today an exclusive distribution agreement for rapid bioburden testing technology. This agreement expands Lonza’s extensive offering of ...
Another driver contributing to the market growth is the growing emphasis on regulatory compliance. Regulatory authorities across the globe are imposing strict guidelines and regulations regarding ...
The quality of water for pharmaceutical production (purified water, water for injection, and ultrapure water) is quantified and regulated through four parameters – total organic carbon (TOC), ...
WILMINGTON, Mass.—October 20, 2014 – Charles River Laboratories International, Inc. (NYSE: CRL) today introduced the PTS-Micro™ system, a new technology platform designed for rapid microbial burden ...
Marketresearch.biz reports that the Rising investments by companies on R&D in lifesciences and increasing product recalls due to microbial contamination are other factors driving growth of the target ...
The bioburden testing market is projected to experience significant growth due to the increasing demand for quality assurance and safety measures in various industries. The rising awareness about the ...
Rapid microbiological testing methods, such as the polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA), are gaining traction in the bioburden testing industry. These methods ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback